Pulse Biosciences Dirección

Dirección controles de criterios 2/4

El CEO de Pulse Biosciences' es Kevin Danahy , nombrado en Sep 2022, tiene una permanencia de 1.58 años. compensación anual total es $5.86M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.065% de las acciones de la empresa, por valor de $245.83K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 6.4 años, respectivamente.

Información clave

Kevin Danahy

Chief Executive Officer (CEO)

US$5.9m

Compensación total

Porcentaje del salario del CEO	7.4%
Permanencia del CEO	1.7yrs
Participación del CEO	0.06%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Danahy en comparación con los beneficios de Pulse Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$6m	US$433k	-US$42m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$350k	-US$59m

Compensación vs. Mercado: La compensación total de Kevin($USD5.86M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Kevin ha aumentado mientras la empresa no es rentable.

CEO

Kevin Danahy (52 yo)

1.7yrs

Permanencia

US$5,864,450

Compensación

Mr. Kevin P. Danahy is Chief Executive Officer of Pulse Biosciences, Inc. from September 2022 and serves as its President from October 2023 and was its President from September 2022 until 2023. He served a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Duggan	Executive Chairman	6.5yrs	US$257.41k	67.86% $ 260.5m
Kevin Danahy	President & CEO	1.7yrs	US$5.86m	0.065% $ 249.4k
Darrin Uecker	CTO & Director	1.7yrs	US$5.39m	0.27% $ 1.1m
Mitchell Levinson	Chief Strategy Officer	2.8yrs	US$1.69m	0.18% $ 696.6k
Richard Nuccitelli	Chief Science Officer	9.5yrs	sin datos	sin datos
Kenneth B. Stratton	General Counsel & Corporate Secretary	3yrs	sin datos	sin datos
Patty Perla	Vice President of Human Resources	4.3yrs	sin datos	sin datos
David Danitz	Senior Vice President of Engineering	2.7yrs	sin datos	sin datos
Gansevoort Dunnington	Chief Medical Officer	less than a year	sin datos	sin datos
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PLSE se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Duggan	Executive Chairman	6.5yrs	US$257.41k	67.86% $ 260.5m
Darrin Uecker	CTO & Director	8.7yrs	US$5.39m	0.27% $ 1.1m
Richard van den Broek	Independent Director	3.8yrs	US$208.89k	0% $ 0
Shelley Spray	Independent Director	2.5yrs	US$123.47k	0% $ 0
Mahkam Zanganeh	Independent Director	7.3yrs	US$173.00k	1.36% $ 5.2m
Manmeet Soni	Lead Independent Director	6.5yrs	US$180.07k	0% $ 0

6.5yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de PLSE se considera experimentada (6.4 años de antigüedad promedio).

Pulse Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

Recent updates

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences gets Health Canada approval for CellFX System

Consensus forecasts updated

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?

Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

Pulse Biosciences establishes at-the-market equity program

New 90-day high: US$36.62

Price target raised to US$40.00